Ventas, Inc. (VTR) — Q2 2026 Earnings Preview

Company

Ventas, Inc.

Ticker

NYSE: VTR

Upcoming Earnings Date

July 30, 2026 (Q2 2026 Earnings Call, 10:00 AM ET)

Preparation Date

July 29, 2026

Sector / Sub-Sector

Healthcare REIT / Senior Housing Operating Portfolio (SHOP)

1. Earnings Preview

Key Takeaway: Setup is constructive but the bar is elevated — consensus expects another strong SHOP beat, and the wildcard is whether the key summer selling season (May–September) delivered the occupancy gains needed to sustain the raised 16% SHOP NOI growth guide.

Heading into Q2 2026, the bar for Ventas is high but achievable: management raised full-year SHOP same-store NOI growth guidance to 16% at the Q1 print and lifted total investment volume guidance to $3 billion, signaling peak confidence in the cycle. Consensus Normalized FFO of ~$0.957/share implies ~9% YoY growth, consistent with the trajectory management has delivered for five consecutive years of double-digit SHOP NOI growth. Estimate revisions have been modestly positive since the Q1 print — the as-of-May 4 baseline of $0.954 has ticked up to $0.957 — suggesting the Street is incrementally more constructive but has not aggressively front-run the print. The stock has been a standout performer, rising ~16% since the April 27 earnings date and ~47% over the trailing twelve months, with the majority of that move driven by multiple expansion (EV/EBITDA from 18.9x to 22.4x) rather than estimate revisions alone, meaning the stock has priced in continued execution. The single biggest wildcard is summer selling season occupancy momentum: management explicitly flagged that Q1's strong start raised the full-year occupancy guide from 270 to 300 bps, but noted that "our success during the key selling season will determine the full year outcome." Any evidence of occupancy deceleration — or, conversely, an acceleration above the 300 bps guide — will be the primary stock driver on print day. The Welltower Q2 2026 print (reported July 27) delivered 330 bps of YoY occupancy growth and raised SHOP NOI guidance to 18.5–21.5%, providing a strong positive read-through for VTR.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a high but achievable bar — SHOP same-store NOI growth of ~16.9% YoY is the primary swing factor, while Normalized FFO/share of $0.957 reflects continued double-digit earnings growth. SHOP occupancy is the leading indicator to watch.

Table 1 — Current Quarter Snapshot (Q2 2026, All Key KPIs)

KPI

Q1 2026 Actual

Q2 2025 Actual (Prior Year)

Q2 2026 Consensus Estimate

YoY Change

Guidance (FY 2026)

Consensus vs. Guidance

Normalized FFO per Share — Diluted ($)

$0.940

$0.891

$0.957

+7.4% YoY

$3.82–$3.89 (mid: $3.855)

FY consensus $3.878 vs. mid $3.855; +0.6% above mid

SHOP Same-Store NOI Growth YoY (%)

+15.4%

+13.3%

~+16.9%

+360 bps vs. Q2 2025

16% at midpoint (raised from 15%)

Consensus ~+90 bps above guidance mid

SHOP Same-Store Occupancy (%)

90.4%

87.7%

~90.9%

+320 bps YoY

~300 bps full-year growth (raised from 270 bps)

Tracking above guidance pace

Avg. Monthly Revenue per Occupied Unit — RevPOR ($)

$5,577

$5,238

~$5,562

+6.2% YoY

~8.75% revenue growth (FY guide)

Consensus slightly below FY revenue guide pace

Acquisition Volume ($M)

$996M

$213M

~$680M

N/M (lumpy)

$3.0B FY 2026 (raised from $2.5B)

FY consensus $2.95B vs. $3.0B guide; ~−1.7% below mid

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 28, 2026. Guidance from Q1 2026 earnings call (April 28, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs)

Normalized FFO per Share — Diluted ($)

Quarter

Reported

Consensus

Surprise %

Result

Q1 2026

$0.940

$0.903

+4.1%

Beat

Q4 2025

$0.890

$0.885

+0.6%

Beat

Q3 2025

$0.895

$0.868

+3.1%

Beat

Q2 2025

$0.891

$0.857

+4.0%

Beat

Q1 2025

$0.865

$0.822

+5.2%

Beat

Q4 2024

$0.829

$0.806

+2.9%

Beat

Q3 2024

$0.814

$0.796

+2.3%

Beat

Q2 2024

$0.891

$0.857

+4.0%

Beat

SHOP Same-Store NOI Growth YoY (%)

Quarter

Reported

Consensus

Surprise (bps)

Result

Q1 2026

+15.4%

+14.3%

+110 bps

Beat

Q4 2025

+15.4%

+16.6%

−120 bps

Miss

Q3 2025

+15.9%

+17.2%

−130 bps

Miss

Q2 2025

+13.3%

+12.5%

+80 bps

Beat

Q1 2025

+13.6%

+13.9%

−30 bps

Slight Miss

Q4 2024

+16.9%

+16.0%

+90 bps

Beat

Q3 2024

+15.3%

+17.4%

−210 bps

Miss

Q2 2024

+13.3%

+12.5%

+80 bps

Beat

Source: Visible Alpha Consensus and Actuals Data. Pattern: VTR has beaten Normalized FFO consensus in all 8 of the last 8 quarters, with an average surprise of +3.3%. SHOP NOI growth has been more mixed vs. elevated consensus expectations, with 4 beats and 4 misses over the same period — reflecting the Street's tendency to set an aggressive bar on this metric.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been raised across all key metrics since the Q4 2025 print, and tone remains highly confident. The only post-Q1 corporate action was the May 15 ATM expansion to $3B — a capital-raising signal consistent with the accelerated $3B investment target, not a guidance change.

Metric

Initial Guidance (Q1 2026 Earnings Call, Apr 28)

Revised Guidance

Current Consensus

Note

Normalized FFO/Share (FY 2026)

$3.82–$3.89 (mid: $3.855)

$3.878

Raised $0.03 at Q1 print vs. prior $3.79–$3.86; no post-Q1 change. Consensus sits $0.023 above midpoint.

SHOP Same-Store NOI Growth (FY 2026)

~16% at midpoint (raised from 15%)

~16.4%

↑ Raised at Q1 2026 earnings (Apr 28); driven by higher occupancy growth expectation. Consensus slightly above midpoint.

Total Company Same-Store NOI Growth (FY 2026)

~10% at midpoint (raised from prior)

~10%

↑ Raised at Q1 2026 earnings; consensus in line with guidance midpoint.

SHOP Occupancy Growth (FY 2026)

~300 bps YoY (raised from 270 bps)

~300 bps

↑ Raised at Q1 2026 earnings; consensus tracking guidance.

Investment Volume (FY 2026)

$3.0B (raised from $2.5B)

~$2.95B

↑ Raised at Q1 2026 earnings; $1.7B already closed YTD as of Q1 print. Consensus slightly below guide.

ATM Equity Program Capacity

N/A (pre-existing program)

Expanded to $3.0B (May 15, 2026 — Amendment No. 3)

N/A

Capital action only; no change to operating guidance. Consistent with $3B investment target funding strategy.

Net Debt / EBITDA

5.0x (Q1 2026 actual); further improvement expected

N/A

10th consecutive quarter of sequential improvement; management expects continued deleveraging through 2026.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved modestly higher since the Q1 print across all key metrics, tracking guidance rather than diverging from it. The gap between consensus and guidance midpoints is narrow and represents a slight cushion rather than a risk — the Street is not aggressively front-running the print.

KPI (Period)

Estimate ~5 Days Post Q1 Earnings (May 4, 2026)

Current Consensus (Jul 28, 2026)

Estimate Δ (%)

Initial Guidance (Q1 Call, Apr 28)

Current Guidance

Guidance Δ

Consensus vs. Guidance (%)

Norm. FFO/Share — Q2 2026

$0.954

$0.957

+0.3%

N/A (quarterly not guided)

N/A

N/A

N/A

Norm. FFO/Share — FY 2026

$3.882

$3.878

−0.1%

$3.82–$3.89 (mid $3.855)

Unchanged

+0.6% above mid

SHOP SS NOI Growth — Q2 2026

~18.4%

~16.9%

−150 bps

N/A (quarterly not guided)

N/A

N/A

N/A

SHOP SS NOI Growth — FY 2026

~17.2%

~16.4%

−~80 bps

~16% at midpoint

Unchanged

+40 bps above mid

SHOP SS Occupancy — Q2 2026

~90.96%

~90.91%

−5 bps

N/A (quarterly not guided)

N/A

N/A

N/A

RevPOR — Q2 2026 ($)

~$5,619

~$5,562

−1.0%

N/A (quarterly not guided)

N/A

N/A

N/A

Source: Visible Alpha Consensus and Actuals Data. Estimates for SHOP NOI growth have been modestly revised down from the immediate post-Q1 baseline (18.4% → 16.9% for Q2), reflecting the Street recalibrating to the 16% FY guidance midpoint rather than extrapolating Q1's 15.4% run-rate. FFO estimates are essentially flat, suggesting no meaningful revision risk in either direction. The gap between consensus and guidance is narrow across all metrics, representing a slight cushion rather than a risk.

5. Stock Performance

Key Takeaway: VTR has surged ~16% since the Q1 2026 earnings date (April 27), dramatically outperforming both XLRE (+5.9%) and the S&P 500 (+3.6%). The 12-month gain of ~47% has been predominantly multiple-expansion driven (EV/EBITDA from 18.9x to 22.4x), meaning the stock has re-rated on the durability of the SHOP growth thesis — not just estimate revisions.

VTR vs. XLRE vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (April 27, 2026). XLRE = Real Estate Select Sector ETF (VTR's sector benchmark). Source: Stock Price Data.

Horizon

VTR Price Change

EV/EBITDA at Start

EV/EBITDA Now (22.4x)

Multiple Δ

Commentary

1 Month

+10.2%

20.7x

22.4x

+8.1%

Multiple expansion dominant; WELL Q2 print (Jul 27) and sector re-rating driving near-term move.

3 Months

+15.9%

20.2x

22.4x

+10.8%

Multiple expansion dominant; Q1 beat and guidance raise catalyzed the move.

6 Months

+28.7%

19.7x

22.4x

+13.7%

Combination of multiple expansion and earnings growth; SHOP thesis gaining broader market acceptance.

12 Months

+47.7%

18.9x

22.4x

+18.3%

Multiple expansion accounts for ~38% of total return; earnings growth accounts for ~62%. Durable re-rating.

Source: Stock Price Data; Visible Alpha Consensus and Actuals Data (EV/EBITDA multiples). Key events since Q1 earnings: (1) May 15 — ATM expanded to $3B; (2) June 15 — General Counsel Carey Roberts resigned to join Blackstone; (3) July 27 — Welltower Q2 2026 beat and guidance raise, driving sector re-rating and VTR to new highs above $100.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is Welltower's Q2 2026 beat and guidance raise (July 27), which provides a direct positive read-through for VTR's SHOP segment and has already driven VTR shares to new highs above $100. The ATM expansion and General Counsel departure are secondary items.

7. Peer Commentary: Current-Quarter Read-Through (Last 60 Days)

Key Takeaway: Peer commentary from the last 60 days is uniformly positive for VTR's Q2 2026 SHOP outlook. Welltower's Q2 2026 print (the most direct read-through) delivered 330 bps of YoY occupancy growth, 20.5% SHOP NOI growth, and a guidance raise — all pointing to a strong Q2 for VTR. AHR's June conference commentary and SBRA's July business update reinforce the sector-wide NOI growth trajectory. All commentary below addresses Q2 2026 current-quarter conditions or forward outlook; no retrospective prior-quarter peer commentary is included.

Welltower (WELL) — Q2 2026 Earnings (Reported July 27, 2026)

Comparability to VTR SHOP: Direct. WELL is VTR's closest peer in senior housing operating portfolio strategy, with SHOP now representing ~70% of WELL's NOI (vs. ~60%+ for VTR). WELL's Q2 2026 results are the single most important read-through for VTR's Q2 print.

Sabra Health Care REIT (SBRA) — Business Update (July 21, 2026)

Comparability to VTR SHOP: Partial. SBRA's Senior Housing Managed portfolio is directly comparable to VTR SHOP. SBRA's triple-net portfolio is partially comparable to VTR's triple-net segment. SBRA is a smaller, more skilled-nursing-focused peer, so the magnitude of growth rates may differ.

American Healthcare REIT (AHR) — Nareit REITweek Conference (June 2, 2026)

Comparability to VTR SHOP: Direct for AHR's traditional SHOP segment; partial for AHR's Trilogy integrated campus segment (unique model). AHR's commentary on occupancy, rate, and transaction environment is directly applicable to VTR SHOP.

8. Insider Transaction Activity

Key Takeaway: Insider activity since the Q1 2026 earnings date is limited to one open-market buy by a Director and one small planned sale by another Director. The open-market purchase by Director Michael Embler (2,500 shares at ~$82/share on June 3) is a modestly positive signal. No clustered selling or unusual activity; overall insider posture is neutral-to-constructive.

Name

Title

Transaction Type

Shares

Est. Value

Transaction Date

Note

Michael J. Embler

Director

Open Market Buy

2,500

~$205,000

June 3, 2026

Discretionary open-market purchase at ~$82/share. Constructive signal — Director buying near post-Q1 levels.

Walter C. Rakowich

Director

Open Market Sale (10b5-1 Planned)

1,152

~$100,000

May 14, 2026

Pre-planned 10b5-1 sale. Small size relative to holdings (28,349 shares post-sale). Routine; not a discretionary signal.

Source: SEC Form 4 Filings (Insider Transaction Data). Window: April 27, 2026 – July 28, 2026 (since Q1 2026 earnings). Open-market transactions (Form 4 codes P/S) only. No executive-level (CEO/CFO/President) transactions were filed in this window. The absence of executive selling is a neutral-to-positive signal given the stock's ~16% appreciation since the Q1 print.